Positive Top-Line Results From Pfizer ’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE) August 30, 2021 -- Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key secondary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials